A Phase IV Study to Evaluate the SUBLOCADE Treatment Exit Strategy
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Sponsors Indivior
Most Recent Events
- 04 Jun 2025 Status changed from active, no longer recruiting to completed.
- 04 Apr 2025 Planned End Date changed from 31 May 2025 to 1 May 2025.
- 04 Apr 2025 Planned primary completion date changed from 30 May 2025 to 1 May 2025.